Chloroquine News and Research

RSS

Can ordinary COVID patients get the Trump treatment? It’s OK to ask

When Terry Mutter woke up with a headache and sore muscles on a recent Wednesday, the competitive weightlifter chalked it up to a hard workout.

20 Oct 2020

Exploring the effects of smoking tobacco on COVID-19 risk

A study conducted by researchers in China has shed light on how certain tobacco compounds might prevent cells from becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

14 Oct 2020

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Study compares the effect of hydroxychloroquine versus favipiravir in SARS-CoV-2−infected hamsters

Virologists at the Rega Institute have shown that the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters.

9 Oct 2020

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.

6 Oct 2020

A special issue on the emerging COVID-19 infection

Acta Pharmaceutica Sinica B publishes special issue on 'Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)' edited by Hai-Bin Luo, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; Shilin Chen, Institute of Chinese Materia Medica, Beijing, China and Peiqing Liu, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.

29 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Cardiovascular adverse events linked to hydroxychloroquine and chloroquine

As the antimalarial drugs hydroxychloroquine and chloroquine have drawn attention as potential therapies for COVID-19 and are being widely used off-label, it's now more important than ever to have a thorough assessment of the safety of these medications.

23 Sep 2020

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.

16 Sep 2020

Azithromycin use for treating COVID-19 may increase risk of cardiac events

Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of COVID-19 have revolved around the drug's reputation for causing cardiac events such as abnormal heart rhythms or beats and cardiac arrest.

16 Sep 2020

Can amodiaquine short circuit this pandemic?

A recent study by the US researchers highlights the value of the human organ chip technology as a more robust and physiologically relevant platform for rapid drug repurposing, and suggest that amodiaquine may be used to prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2020

Identifying, preventing and treating drug-induced arrhythmias

Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.

15 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Scientists describe known approaches for treatment of SARS-CoV-2 infection

Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.

29 Aug 2020

Study: Hydroxychloroquine plus azithromycin linked to significant cardiovascular risks

The combination of hydroxychloroquine (HCQ) and azithromycin (AZM) has been linked to significant cardiovascular risks, including mortality, in the largest safety study ever performed on both HCQ and HCQ+AZM.

25 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

COVID-19 should be treated as an acute inflammatory disease, Massey scientist says

The COVID-19 pandemic has had detrimental effects on global infrastructure sectors, including economic, political, health care, education and research systems, and there is still no definitive treatment strategy for the disease.

5 Aug 2020

Scientists detect emergence and spread of artemisinin-resistant malaria parasites in Rwanda

Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.

5 Aug 2020